fda warning letter semaglutide october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of GLP-1 Pipeline Update: May 2025

Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist currently under clinical investigation and not licensed by the MHRA or EMA for use in the UK

One argument compounders have made to defend their ability to make copy-cat products is that they are providing unique dosage forms (i.e., single-dose vials for self-administration vs

Bodybuilders are using 1mg (not a micro-dose, obviously) retatrutide and having amazing results

BMI should not be used alone to assess a persons health.

Effects of medium- and long-chain structured triacylglycerol on the therapeutic efficacy of vitamin D on ulcerative colitis: a consideration for efficient lipid delivery systems

Mounjaro is a medication approved for adults with type 2 diabetes and should be used with diet and exercise